(NASDAQ: QNRX) Quoin Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Quoin Pharmaceuticals's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast QNRX's revenue for 2026 to be $195,506,710, with the lowest QNRX revenue forecast at $0, and the highest QNRX revenue forecast at $402,524,179. On average, 4 Wall Street analysts forecast QNRX's revenue for 2027 to be $1,122,269,595, with the lowest QNRX revenue forecast at $697,281,818, and the highest QNRX revenue forecast at $1,563,437,036.
In 2028, QNRX is forecast to generate $2,237,902,886 in revenue, with the lowest revenue forecast at $2,150,162,716 and the highest revenue forecast at $2,303,737,378.